Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TAC01-CLDN18.2 |
| Trade Name | |
| Synonyms | TAC01 CLDN18.2 |
| Drug Descriptions |
TAC01-CLDN18.2 are T-lymphocytes engineered to express a T-cell antigen coupler (TAC) targeting CLDN18.2, which potentially inhibit growth of CLDN18.2-expressing tumors (Journal for ImmunoTherapy of Cancer 2022;10). |
| DrugClasses | CLDN18.2 Immune Cell Therapy 4 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| TAC01-CLDN18.2 | TAC01-CLDN18.2 | 0 | 1 |